Polymyalgia rheumatica is a form of inflammatory arthritis that commonly affects the muscles around the neck, shoulder and hip areas. The disease primarily occurs in adults aged 50 years and above. Some common symptoms include pain and stiffness in the neck, shoulder and pelvic areas. Drugs used for the treatment of polymyalgia rheumatica include corticosteroids like prednisone and low-dose aspirin. Favorable research and development activities for developing novel targeted therapies are underway to reduce long-term steroid use risks.
The polymyalgia rheumatica drugs market is estimated to be valued at USD 266 Mn in 2024 and is expected to reach USD 662 Mn by 2031, growing at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2031.
Key players operating in the polymyalgia rheumatica drugs market are copyright Inc., Bristol-Myers Squibb Company, Sanofi and Novartis AG. Companies are investing in clinical trials to develop more effective therapeutics with reduced side effects.
The rising incidence and prevalence of Polymyalgia Rheumatica Drugs Market, especially in aging populations primarily drives the market growth. As per estimates, over 1 million Americans suffer from polymyalgia rheumatica every year.
Technological advancements to develop targeted therapies could help reduce corticosteroid use and associated risks like bone loss, weight gain and diabetes. Biologics demonstrating promising results in rheumatoid arthritis are being explored for polymyalgia rheumatica treatment.
Market Trends
Growing preference for oral formulations - Oral corticosteroids like prednisone are widely used but have several adverse effects with long-term usage. Companies are developing oral therapies combining corticosteroids with additional immuno-modulating drugs to reduce dosage and side effects.
Increased focus on biosimilars - Biosimilars demonstrating efficacy in arthritis are being evaluated for polymyalgia rheumatica. Their cost-effectiveness could boost widespread adoption in treatment.
Market Opportunities
Exploring IL-6 inhibitors - Drugs targeting IL-6, a pro-inflammatory cytokine associated with polymyalgia rheumatica, show potential. Tocilizumab already approved for rheumatoid arthritis is under clinical evaluation.
Personalized therapy options - Biomarker research can help predict disease course and response to therapy, enabling customized long-term treatment plans. This represents a major opportunity.
Impact of COVID-19 on Polymyalgia Rheumatica Drugs Market
The COVID-19 pandemic has disrupted healthcare systems globally and impacted the growth of polymyalgia rheumatica drugs market. During the pandemic, non-emergency hospital visits and treatments saw a decline as people avoided hospitals due to the risk of viral transmission. This affected the diagnosis and management of polymyalgia rheumatica, leading to a drop in demand for corticosteroid and immunosuppressant drugs used for its treatment.
However, as the pandemic progresses, healthcare facilities are adapting to provide continuity of care for chronic conditions like polymyalgia rheumatica while following safety protocols. Telehealth and remote patient monitoring solutions are being used more widely to help manage the condition without exposing patients to infection risk. Drug manufacturers have stepped up production to ensure adequate supply. It is expected that with increased vaccination drives worldwide, regular healthcare access will be restored steadily in post-COVID times.
In terms of geography, North America holds the major share of the polymyalgia rheumatica drugs market in terms of value. This is attributed to the growing elderly population suffering from the condition in countries like the United States. Europe accounts for the second largest market owing to rising prevalence rates. Asia Pacific is positioned as the fastest growing region for polymyalgia rheumatica drugs market driven by improving access to healthcare in emerging nations and growing medical awareness.
The Middle East and Africa region is concentrating efforts on strengthening its healthcare infrastructure to efficiently diagnose and manage chronic diseases among the population. Government initiatives are being undertaken to enhance diagnostic capabilities and develop centralized databases for conditions like polymyalgia rheumatica. This will help expand penetration of effective treatment options in the coming years.
Get more insights on: Polymyalgia Rheumatica Drugs Market
Get this Report in Japanese Language: リウマチ性多発筋痛症治療薬市場
Get this Report in Korean Language: 다발성 근육통 류마티스 약물 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)